Multianalyte Assays with Algorithmic Analyses Codes

This document contains new administrative codes for Multianalyte Assays with Algorithmic Analyses (MAAA) procedures that have been approved since the most recent release of the CPT® data files (August 31) and are provided to facilitate accurate reporting of MAAA procedures.

To assist users in reporting the most recently approved administrative MAAA codes, this document will be updated with early publication of these codes in July, January, and March in a given CPT cycle. These dates for early release coincide with completion of Panel actions following each of the three CPT Editorial Panel meetings in a given CPT cycle (May, October, and February).

<table>
<thead>
<tr>
<th>MAAA Codes</th>
<th>Panel Meeting Approval</th>
<th>Publication</th>
<th>Effective Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Administrative MAAA</td>
<td>May,</td>
<td>July 1</td>
<td>January 1</td>
</tr>
<tr>
<td>Administrative MAAA</td>
<td>October,</td>
<td>January 1</td>
<td>July 1</td>
</tr>
<tr>
<td>Administrative MAAA</td>
<td>February</td>
<td>March 1</td>
<td>July 1</td>
</tr>
</tbody>
</table>

For these codes, as well as other CPT codes, inclusion of a descriptor and its associated code number in the CPT code set does not represent endorsement by the AMA of any particular diagnostic procedure or service. Inclusion or exclusion of a procedure or service does not imply any health insurance coverage or reimbursement policy.

It is important to note that further CPT Editorial Panel or Executive Committee actions may affect these codes and/or descriptors. For this reason, code numbers and/or descriptor language may differ at the time of publication in the CPT codebook. In addition, further Panel actions may result in gaps in code number sequencing.

Background Information for Multianalyte Assays with Algorithmic Analyses

MAAAs are procedures that utilize multiple results derived from panels of analyses of various types, including molecular pathology assays, fluorescent in situ hybridization assays and non-nucleic acid based assays (eg, proteins, polypeptides, lipids, carbohydrates). Algorithmic analysis, using the results of these assays as well as other patient information (if used), is then performed and reported typically as a numeric score(s) or as a probability. The results of individual component procedure(s) that are inputs to the MAAAs may be provided on the associated laboratory report; however, these assays are not reported separately using additional codes.

The MAAA procedure codes encompass all analytical services required for the algorithmic analysis (eg, cell lysis, nucleic acid stabilization, extraction, digestion, amplification, hybridization and detection) in addition to the algorithmic analysis itself. Procedures that are required prior to cell lysis (eg, microdissection codes 88380 and 88381) should be reported separately.
The format for the code descriptor usually includes (in order):

- Disease type (eg, oncology, autoimmune, tissue rejection),
- Material(s) analyzed (eg, DNA, RNA, protein, antibody),
- Number of markers (eg, number of genes, number of proteins),
- Methodology(s) (eg, microarray, real-time [RT]-PCR, in situ hybridization [ISH], enzyme linked immunosorbent assays [ELISA]),
- Number of functional domains (if indicated),
- Specimen type (eg, blood, fresh tissue, formalin-fixed paraffin embedded),
- Algorithm result type (eg, prognostic, diagnostic),
- Report (eg, probability index, risk score)

By their nature, MAAA procedures are typically unique to a single clinical laboratory or manufacturer. There are two categories of MAAA procedure codes: Category I and administrative. For inclusion in the MAAA administrative coding set, an analysis must be generally available for patient care. The AMA has not reviewed MAAA administrative codes for clinical utility. As opposed to Category I MAAA codes, the MAAA administrative codes are identified by a four-digit number followed by the letter M.

In order to report a MAAA code, the analysis performed must fulfill the code descriptor and, if proprietary, must be the test represented by the proprietary name listed in Appendix O of the CPT codebook. When a specific MAAA procedure is not included in the Category I MAAA section or in Appendix O, the MAAA unlisted code (81599) should be used.

### MAAA Administrative Codes

<table>
<thead>
<tr>
<th>Proprietary Name and Clinical Laboratory or Manufacturer</th>
<th>Alpha-Numeric Code</th>
<th>Publication &amp; Effective Dates</th>
<th>Code Descriptor</th>
</tr>
</thead>
<tbody>
<tr>
<td>*4Kscore™ Test, OPKO Diagnostics, LLC</td>
<td>▲0010M</td>
<td><strong>Revision Published:</strong> March 22, 2016  <strong>Effective:</strong> July 1, 2016</td>
<td>Oncology (High-Grade Prostate Cancer), biochemical assay of four proteins (Total PSA, Free PSA, Intact PSA and human kallikrein 2 [hK2]) plus patient age, digital rectal examination status, and no history of positive prostate biopsy, utilizing plasma or serum, prognostic algorithm reported as a probability score</td>
</tr>
</tbody>
</table>

*the revision of the descriptor for this test reflects a change in test specimen type to include serum. Amendment of the code descriptor reflects the determination that the revision reflects a change in the description of the specimen “matrix”, and as such, does not constitute a significant change in the assay.*